NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma
about
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Chimeric antigen receptor therapy for cancerFeasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Minimal residual disease following allogeneic hematopoietic stem cell transplantation.National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committeeProphylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationFactors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplDonor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Current status of chimeric antigen receptor therapy for haematological malignancies.ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin.
P2860
Q26830857-10A18D11-44E1-4B5C-960B-779BF815CC3CQ27013599-269614B9-5255-46CB-B657-2D010F69A8ABQ33831349-960C7ABE-AB71-4160-A2B3-3AF39666017BQ34667390-113C380B-79C1-4FBB-A0A5-6E0E0C17462AQ35008021-C5B86B2B-CAC5-474B-AD45-5B56C43B2ED5Q35100974-98634F74-CD6A-43DA-B6E6-04B824929656Q35588845-67C02909-C32C-4C00-9D27-554327610E9CQ35752737-82DFFD75-B3FD-4E78-9DCF-BDC8D1868782Q36107961-573CFD47-BFF7-48DC-A08C-935A814C3994Q37000485-0E710B3F-7B8F-467C-B46D-2450D7D20488Q37148120-6C28B293-FD4B-4776-908D-69F4E5FB65C4Q37359736-1DD12C88-E8F5-468B-888D-4F5216B47359Q37431934-AC5E9401-7D9B-4DE8-BB2F-58ECDAF1451EQ37609957-77CE6DB1-8A2B-4543-9244-2855B73CD718Q37832506-A9A64586-9DCC-44E5-A06C-BDCE7C3EFCB1Q38631108-3E896107-52A2-47C8-A80E-E1ADF57560D2Q40852245-A87F813F-2E86-45FF-AF14-3714A5E351FFQ41480472-15CC38D4-9BDA-42DD-8A98-2F0C3726A89AQ41661692-648ABCBB-78E6-406A-A73D-1463CABF1346Q46263769-A225A771-C467-48CF-A039-F9CCD3948912Q49894494-28AC61AF-6FD0-430B-A12A-01AB07889E5A
P2860
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
NCI First International Worksh ...... splantation for hematologic ma
@ast
NCI First International Worksh ...... splantation for hematologic ma
@en
type
label
NCI First International Worksh ...... splantation for hematologic ma
@ast
NCI First International Worksh ...... splantation for hematologic ma
@en
prefLabel
NCI First International Worksh ...... splantation for hematologic ma
@ast
NCI First International Worksh ...... splantation for hematologic ma
@en
P2093
P2860
P1476
NCI First International Worksh ...... splantation for hematologic ma
@en
P2093
Daniel J DeAngelo
Donna Przepiorka
Edwin P Alyea
James W Young
Jeffrey Moldrem
John M Pagel
Michael Bishop
Michel Sadelin
Stan Riddell
P2860
P304
P356
10.1016/J.BBMT.2010.05.005
P577
2010-05-24T00:00:00Z